These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11822103)

  • 1. [Losartan and the kidney protection. The RENAAL study].
    Recenti Prog Med; 2001 Dec; 92(12):788. PubMed ID: 11822103
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
    MMW Fortschr Med; 2005 May; 147(19):49. PubMed ID: 15940939
    [No Abstract]   [Full Text] [Related]  

  • 8. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
    Nilsson P; Attvall S
    Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
    [No Abstract]   [Full Text] [Related]  

  • 9. [The RENAAL Study. Effect of losartan on diabetic nephropathy].
    Kuhlmann MK; Köhler H
    Internist (Berl); 2002 May; 43(5):675-7. PubMed ID: 12085539
    [No Abstract]   [Full Text] [Related]  

  • 10. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics.
    Cardiovasc J Afr; 2008; 19(4):226. PubMed ID: 18776973
    [No Abstract]   [Full Text] [Related]  

  • 12. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
    Rachmani R; Levi Z; Zadok BS; Ravid M
    Clin Pharmacol Ther; 2002 Sep; 72(3):302-7. PubMed ID: 12235451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-Il-receptor blockers and nephropathy in patients with type 2 diabetes.
    Farquhar D
    CMAJ; 2001 Nov; 165(10):1379. PubMed ID: 11760990
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
    Tershakovec AM; Keane WF; Zhang Z; Lyle PA; Appel GB; McGill JB; Parving HH; Cooper ME; Shahinfar S; Brenner BM
    Diabetes Care; 2008 Mar; 31(3):445-7. PubMed ID: 18070995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A; Amer W; Anwar E; Bashir K
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieved vs initial blood pressure in predicting renal outcomes.
    Onuigbo MA
    Arch Intern Med; 2004 Jan; 164(2):223; author reply 223-4. PubMed ID: 14744850
    [No Abstract]   [Full Text] [Related]  

  • 19. Losartan in diabetic nephropathy.
    Carswell CI; Goa KL
    Drugs; 2003; 63(4):407-14; discussion 415-6. PubMed ID: 12558462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
    MMW Fortschr Med; 2001 Oct; 143(43):50. PubMed ID: 11715881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.